Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis
The LancetPublished 1 December 2005
Juan P. Casas, Weiliang Chua, Stavros Loukogeorgakis, Patrick Vallance, Liam Smeeth, Aroon D. Hingorani
Citations744
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The benefits of ACE inhibitors or ARBs on renal outcomes in placebo-controlled trials probably result from a blood-pressure-lowering effect, and in patients with diabetes, additional renoprotective actions of these substances beyond lowering blood pressure remain unproven.
Abstract
The benefits of ACE inhibitors or ARBs on renal outcomes in placebo-controlled trials probably result from a blood-pressure-lowering effect. In patients with diabetes, additional renoprotective actions of these substances beyond lowering blood pressure remain unproven, and there is uncertainty about the greater renoprotection seen in non-diabetic renal disease.
Keywords
Medicine
The LancetAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
10,121 Citations2002Sarah Lewington, Robert Clarke +3 more
Throughout middle and old age, usual blood pressure is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg.
Practical Statistics for Medical Research
9,764 Citations1990Douglas G. Altman
BMC Medical Research MethodologyEstimating the mean and variance from the median, range, and the size of a sample
9,135 Citations2005Stela Pudar Hozo, Benjamin Djulbegović +1 more
New England Journal of MedicineEffects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
8,611 Citations2000Salim Yusuf
Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure in a two-by-two factorial study evaluating ramipril and vitamin E.
New England Journal of MedicineRenoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
5,920 Citations2001Edmund J. Lewis, Lawrence G. Hunsicker +8 more
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
New England Journal of MedicineThe Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
5,377 Citations1993Edmund J. Lewis, Lawrence G. Hunsicker +2 more
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
The LancetEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
3,195 Citations2000
Ramipril was beneficial for cardiovascular events and overt nephropathy in people with diabetes and the cardiovascular benefit was greater than that attributable to the decrease in blood pressure.
The LancetRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
3,161 Citations2001Stephen MacMahon
This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.
The LancetEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
2,406 Citations2003F. Turnbull
There were no significant differences in total major cardiovascular events between regimens based on ACE inhibitors, calcium antagonists, or diuretics or beta blockers, although ACE-inhibitor-based regimens reduced blood pressure less.
Journal of Clinical EpidemiologyPublication and related bias in meta-analysis
2,207 Citations2000Jonathan A C Sterne, David J. Gavaghan +1 more
Tests for small-study effects should routinely be performed in meta-analysis, particularly for moderate amounts of bias or meta-analyses based on a small number of small studies.
The LancetEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
2,134 Citations2003Kim Fox
Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome, and these benefits were consistent in all predefined subgroups and secondary endpoints.
PubMedEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
2,103 Citations2000Jfe Mann, Hertzel C. Gerstein +1 more
JAMAAssociation of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease
2,036 Citations1998John Danesh, Rory Collins +2 more
The published results from these prospective studies are remarkably consistent for each factor, indicating moderate but highly statistically significant associations with CHD, even though mechanisms that might account for these associations are not clear.
The LancetISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
1,817 Citations1995
58,050 patients entering hospitals up to 24 h after the onset of suspected acute myocardial infarction with no clear contraindications to the study treatments were randomised in a "2 x 2 x 2 factorial" study, reassuring a bout the safety of using nitrates early in acute MI.
Journal of Psychosomatic ResearchPractical statistics for medical research
1,664 Citations1992Michael King
New England Journal of MedicineBlood Pressure and End-Stage Renal Disease in Men
1,645 Citations1996Michael J. Klag, Paul K. Whelton +6 more
Elevations of blood pressure are a strong independent risk factor for end-stage renal disease; interventions to prevent the disease need to emphasize the prevention and control of both high-normal and high blood pressure.
Journal of Human HypertensionGuidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV
1,277 Citations2004Bryan Williams, N. Poulter +6 more
Advice on life-style modifications for all people with high blood pressure (BP) and those with borderline or high-normal BP is provided and there are compelling indications and contraindications for specific classes of antihypertensive drugs, and these are specified.
Annals of Internal MedicineAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease
1,093 Citations2001Tazeen H. Jafar, Christopher H. Schmid +18 more
Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease and is greater in patients with proteinuria.
Archives of Internal MedicineEffects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus
798 Citations2005Fiona Turnbull
These overviews showed that the short- to-medium-term effects on major cardiovascular events of the BP-lowering regimens studied were broadly comparable for patients with and without diabetes.
The LancetBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
591 Citations2004Michael A. Weber, Stevo Julius +12 more
Reaching blood pressure control by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just 1 month of treatment predicted events and survival.
BMJMisleading meta-analysis
506 Citations1995Matthias Egger, George Davey Smith
A meta-analysis of treatments in myocardial infarction published in 1992 retrospectively showed that streptokinase was associated with a highly significant fall in mortality by 1977, but it was not widely recommended until 10 years later—after the effect was confirmed in two mega trials.
Annals of Internal MedicineEffect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease
429 Citations1997Ioannis Giatras, Joseph Lau +1 more
Neither the magnitude of the beneficial effect nor the safety of ACE inhibition was established conclusively, and it remains uncertain whether ACE inhibitors are preferable to other antihypertensive agents in the treatment of nondiabetic renal disease.
BMJEffects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review
382 Citations2004Giovanni FM Strippoli, Maria E. Craig +3 more
Although the survival benefits of ACE inhibitors for patients with diabetic nephropathy are known, the relative effects ofACE inhibitors and AIIRAs on survival are unknown owing to the lack of adequate head to head trials.
HypertensionBlood Pressure Predicts Risk of Developing End-Stage Renal Disease in Men and Women
364 Citations2003Masahiko Tozawa, Kunitoshi Iseki +4 more
Control of blood pressure within normal levels should be stressed as a strategy to prevent end‐stage renal disease in both men and women.
Archives of Internal MedicineRenal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic
341 Citations2005Mahboob Rahman
In hypertensive patients with reduced GFR, neither amlodipine nor lisinopril was superior to chlorthalidone in reducing the rate of development of ESRD or a 50% or greater decrement in GFR.
BMJEffects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials.
337 Citations1991Koon Teo, Salim Yusuf +3 more
It is suggested that intravenous magnesium therapy may reduce mortality in patients with acute myocardial infarction, and further large scale trials to confirm or refute these findings are desirable.
Health Technology AssessmentLowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy
328 Citations2003Matthew Law, Nicholas Wald +1 more
The evidence presented indicates that three drugs in combination may reduce stroke by about two-thirds and ischaemic heart disease by half and the term hypertension should be avoided because it is not a disease and it implies another category who would not benefit from lowering blood pressure.
American Heart JournalElevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials
324 Citations1999Jiang He, Paul K. Whelton
Pooling of the data available from randomized controlled trials indicates that an average reduction of 12 to 13 mm Hg in systolic blood pressure over 4 years of follow-up is associated with a 21% reduction in coronary heart disease, 37% reduction In stroke, 25% reductionIn total cardiovascular mortality, and 13% reductionin all-cause mortality rates.
Journal of HypertensionFollow-up of renal function in treated and untreated older patients with isolated systolic hypertension
122 Citations2001S. Voyaki, Jan A. Staessen +10 more
Antihypertensive treatment starting with the dihydropyridine calcium-channel blocker, nitrendipine, did not decrease blood pressure at the expense of renal function and prevented the development of proteinuria, especially in diabetic patients.
BMJMagnesium in acute myocardial infarction
80 Citations1995Salim Yusuf, Marcus Flather
An informal review of the results of the early clinical trials in acute myocardial infarction indicated a trend towards a lower mortality with intravenous magnesium, with this difference being statistically significant in only one trial.